Abstract
Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disease
characterized by a complex, heterogeneous pathogenesis including inflammation, skin barrier dysfunction and immune dysregulation. Soybean tar, prepared by dry distillation of Sojae Semen Nigrum, has been used as a key drug in AD management for centuries in China. It was claimed that supercritical-CO2 extract of Sojae Semen Nigrum (SSNE) is a substitute of soybean tar. The aim of this study was to investigate the anti-AD effects, mechanisms, and compounds of SSNE.
Methods: SSNE was prepared using supercritical fluid CO2 extraction. TNF-α/IFN-γ-stimulated HaCaT keratinocyte cells were used to evaluate the in vitro anti-AD effects of SSNE. RNA-seq analyses, RT-qPCR, GC-MS, and network pharmacology were used to uncover the mechanisms and compounds responsible for the anti-AD effects of SSNE.
Results: SSNE inhibited hyper-migration and apoptosis of TNF-α/IFN-γ-stimulated
HaCaT cells. Expression levels of the AD markers CCL17 and CCL22 were lowered
by SSNE. RNA-seq analyses demonstrated that SSNE reversed the transcriptome of
TNF-α/IFN-γ-stimulated cells toward non-stimulated cells. Enrichment analyses
indicated that the TNF signaling pathway is one of the key pathways involved in the anti-AD effects of SSNE. RT-qPCR showed that SSNE significantly downregulated TNF signaling components implicated in AD pathogenesis, including inflammation-related genes (IL1B, IL1A, IL1R2, IL17R and LTB), skin barrier-related genes (VEGFC, MMP9, MMP25 and TNFRSF6B) and immune-related genes (IL-33, CCL2, CXCL5 and CXCL8), in a dose-dependent manner. GC-MS and network pharmacology analyses suggested that linolelaidic acid and linoleic acid are the main anti-AD compounds of SSNE.
Conclusions: SSNE has anti-AD potential; inhibition of TNF signaling is probably one of the mechanisms of action of SSNE; linolelaidic acid and linoleic acid are the main anti-AD compounds of SSNE. These findings provide a pharmacological basis for developing SSNE as a new anti-AD agent.
characterized by a complex, heterogeneous pathogenesis including inflammation, skin barrier dysfunction and immune dysregulation. Soybean tar, prepared by dry distillation of Sojae Semen Nigrum, has been used as a key drug in AD management for centuries in China. It was claimed that supercritical-CO2 extract of Sojae Semen Nigrum (SSNE) is a substitute of soybean tar. The aim of this study was to investigate the anti-AD effects, mechanisms, and compounds of SSNE.
Methods: SSNE was prepared using supercritical fluid CO2 extraction. TNF-α/IFN-γ-stimulated HaCaT keratinocyte cells were used to evaluate the in vitro anti-AD effects of SSNE. RNA-seq analyses, RT-qPCR, GC-MS, and network pharmacology were used to uncover the mechanisms and compounds responsible for the anti-AD effects of SSNE.
Results: SSNE inhibited hyper-migration and apoptosis of TNF-α/IFN-γ-stimulated
HaCaT cells. Expression levels of the AD markers CCL17 and CCL22 were lowered
by SSNE. RNA-seq analyses demonstrated that SSNE reversed the transcriptome of
TNF-α/IFN-γ-stimulated cells toward non-stimulated cells. Enrichment analyses
indicated that the TNF signaling pathway is one of the key pathways involved in the anti-AD effects of SSNE. RT-qPCR showed that SSNE significantly downregulated TNF signaling components implicated in AD pathogenesis, including inflammation-related genes (IL1B, IL1A, IL1R2, IL17R and LTB), skin barrier-related genes (VEGFC, MMP9, MMP25 and TNFRSF6B) and immune-related genes (IL-33, CCL2, CXCL5 and CXCL8), in a dose-dependent manner. GC-MS and network pharmacology analyses suggested that linolelaidic acid and linoleic acid are the main anti-AD compounds of SSNE.
Conclusions: SSNE has anti-AD potential; inhibition of TNF signaling is probably one of the mechanisms of action of SSNE; linolelaidic acid and linoleic acid are the main anti-AD compounds of SSNE. These findings provide a pharmacological basis for developing SSNE as a new anti-AD agent.
| Original language | English |
|---|---|
| Publication status | Published - 29 Oct 2022 |
| Event | The Global Conference on Evidence-based Traditional Medicine, GCETM 2022 - Virtual, Penang, Malaysia Duration: 29 Oct 2022 → 30 Oct 2022 https://gcetm2022.com/ https://gcetm2022.com/program/ |
Conference
| Conference | The Global Conference on Evidence-based Traditional Medicine, GCETM 2022 |
|---|---|
| Country/Territory | Malaysia |
| City | Penang |
| Period | 29/10/22 → 30/10/22 |
| Internet address |